/POLB.L

POLB.L Stock - Poolbeg Pharma PLC

Q: What is the analyst price target for POLB.L?

Analyst price target information is not currently available for POLB.L.

Q: What is POLB.L's market cap?

Market capitalization information is not currently available for POLB.L.

Healthcare|Biotechnology|LSE

$4.00-2.44%

$0.10 (-2.44%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $4.40

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for POLB.L

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.00

52W High$7.50

52W Low$2.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A
Gross Profit	$-114,000	$-26,000	$-26,000	$-18,000
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-6,618,000	$-5,039,000	$-4,986,000	$-2,378,000
Net Income	$-5,790,000	$-3,931,000	$-4,686,000	$-2,336,000
Net Margin	N/A	N/A	N/A	N/A
EPS	$-0.01	$-7.90	$-9.37	$-4.67

Company Overview

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Visit Website

Earnings History & Surprises

POLB.L

Beat Rate

Last 3 quarters

Avg Surprise

-66864.4%

EPS vs Estimate

Beats / Misses

0/2

1 met exactly

Latest EPS

$-0.00

Q3 2025

EPS Surprise History

Q4 21

No data

Q3 22

-100337.5%

$-3.21vs$-0.00

Q1 23

No data

Q3 23

No data

Q2 24

No data

Q3 24

-100255.6%

$-4.52vs$-0.00

Q2 25

No data

Q3 25

0.0%

$-0.00vs$-0.00

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 18, 2026	—	—	—	—
Q3 2025	Sep 29, 2025	$-0.00	$-0.00	0.0%	= MET
Q2 2025	May 20, 2025	—	$-0.01	—	—
Q3 2024	Sep 18, 2024	$-0.00	$-4.52	-100255.6%	✗ MISS
Q2 2024	Apr 30, 2024	—	$-4.28	—	—
Q3 2023	Sep 13, 2023	—	$-3.62	—	—
Q1 2023	Mar 30, 2023	—	$-6.16	—	—
Q3 2022	Sep 6, 2022	$-0.00	$-3.21	-100337.5%	✗ MISS
Q4 2021	Dec 31, 2021	—	$-2.34	—	—
Q2 2021	Jun 30, 2021	—	$-2.34	—	—